ATE459653T1 - Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen - Google Patents

Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen

Info

Publication number
ATE459653T1
ATE459653T1 AT06795343T AT06795343T ATE459653T1 AT E459653 T1 ATE459653 T1 AT E459653T1 AT 06795343 T AT06795343 T AT 06795343T AT 06795343 T AT06795343 T AT 06795343T AT E459653 T1 ATE459653 T1 AT E459653T1
Authority
AT
Austria
Prior art keywords
antibodies
tumor cells
monoclonal anti
malignant tumor
treating malignant
Prior art date
Application number
AT06795343T
Other languages
English (en)
Inventor
Laurence Boumsell
Jean Kadouche
Armand Bensussan
Original Assignee
Inst Nat Sante Rech Med
Monoclonal Antibodies Therapeu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Monoclonal Antibodies Therapeu filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE459653T1 publication Critical patent/ATE459653T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06795343T 2005-06-15 2006-06-14 Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen ATE459653T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/154,262 US7736647B2 (en) 2005-06-15 2005-06-15 Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
PCT/IB2006/002331 WO2007000671A2 (en) 2005-06-15 2006-06-14 Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells

Publications (1)

Publication Number Publication Date
ATE459653T1 true ATE459653T1 (de) 2010-03-15

Family

ID=37573538

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06795343T ATE459653T1 (de) 2005-06-15 2006-06-14 Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen

Country Status (10)

Country Link
US (2) US7736647B2 (de)
EP (1) EP1896507B1 (de)
JP (1) JP5185815B2 (de)
AT (1) ATE459653T1 (de)
CA (1) CA2612486A1 (de)
DE (1) DE602006012672D1 (de)
DK (1) DK1896507T3 (de)
ES (1) ES2341625T3 (de)
PL (1) PL1896507T3 (de)
WO (1) WO2007000671A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010046094A1 (en) * 2008-10-23 2010-04-29 F. Hoffmann-La Roche Ag Determination of immunoglobulin encoding nucleid acid
CA2768658C (en) * 2009-07-22 2018-04-03 Actinium Pharmaceuticals, Inc. Methods for generating radioimmunoconjugates
WO2011130164A2 (en) * 2010-04-13 2011-10-20 The Regents Of The University Of California Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
FR2959416B1 (fr) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
EA034333B1 (ru) 2010-11-30 2020-01-29 Дженентек, Инк. Варианты антитела для переноса соединения через гематоэнцефалический барьер
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
MY171343A (en) * 2011-04-22 2019-10-09 Aptevo Res & Development Llc Prostate-specific membrane antigen binding proteins and related composition and methods
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
EP3559049A4 (de) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Polypeptidkonstrukte und anwendungen davon
CN109369808B (zh) 2012-08-24 2023-11-07 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
BR112017023868A2 (pt) 2015-05-04 2018-07-24 Cytomx Therapeutics Inc anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
EP4029880A1 (de) 2015-05-04 2022-07-20 CytomX Therapeutics, Inc. Aktivierbare anti-cd71-antikörper und verfahren zur verwendung davon
WO2017015227A1 (en) 2015-07-17 2017-01-26 The Trustees Of Columbia University In The City Of New York Methods of treating cd166-expressing cancer
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
EP3423089A4 (de) 2016-03-04 2019-10-23 JN Biosciences, LLC Anti-tigit-antikörper
MA45328A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
WO2017221883A1 (ja) 2016-06-20 2017-12-28 武田薬品工業株式会社 抗体-薬物コンジュゲート
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
EP3554561B1 (de) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137-bindende fibronectin-typ-iii-domänen
US10626165B2 (en) 2016-12-14 2020-04-21 Janssen Biotech, Inc. CD8a-binding fibronectin type III domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
KR20190134654A (ko) 2017-03-09 2019-12-04 싸이톰스 테라퓨틱스, 인크. Cd147 항체, 활성화가능한 cd147 항체, 그리고 이를 만들고, 이용하는 방법
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EP3762420A1 (de) 2018-03-09 2021-01-13 CytomX Therapeutics, Inc. Aktivierbare cd147-antikörper und verfahren zur herstellung und verwendung davon
KR102258014B1 (ko) * 2019-05-15 2021-05-27 강원대학교 산학협력단 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용
KR102258015B1 (ko) * 2019-05-15 2021-05-27 강원대학교 산학협력단 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용
EP3999544A4 (de) * 2019-07-19 2023-08-09 Wuxi Xdc Singapore Private Limited Polypeptidkomplex zur konjugation und seine verwendung
JP2022548310A (ja) 2019-09-23 2022-11-17 シートムエックス セラピューティクス,インコーポレイテッド 抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
JP2022551204A (ja) * 2019-10-14 2022-12-07 アロ・バイオセラピューティクス・カンパニー Cd71結合フィブロネクチンiii型ドメイン
PE20231078A1 (es) 2020-06-02 2023-07-17 Arcus Biosciences Inc Anticuerpos anti-tigit
US11827702B2 (en) 2021-09-01 2023-11-28 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308626A (en) 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
EP0525005B1 (de) 1990-03-27 1997-06-11 The Salk Institute For Biological Studies Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen
US5762932A (en) 1990-04-26 1998-06-09 University Of Iowa Research Foundation Combined treatment of iron depletion and IgG antibody
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
JP4824025B2 (ja) 2004-06-07 2011-11-24 マクロジェニックス ウエスト,インコーポレイテッド トランスフェリンレセプター抗体

Also Published As

Publication number Publication date
CA2612486A1 (en) 2007-01-04
EP1896507A2 (de) 2008-03-12
PL1896507T3 (pl) 2010-08-31
US20110311544A1 (en) 2011-12-22
DE602006012672D1 (de) 2010-04-15
US20060286030A1 (en) 2006-12-21
US8409573B2 (en) 2013-04-02
JP2009509497A (ja) 2009-03-12
WO2007000671A3 (en) 2007-04-26
JP5185815B2 (ja) 2013-04-17
US7736647B2 (en) 2010-06-15
WO2007000671A2 (en) 2007-01-04
DK1896507T3 (da) 2010-06-07
EP1896507B1 (de) 2010-03-03
ES2341625T3 (es) 2010-06-23

Similar Documents

Publication Publication Date Title
ATE459653T1 (de) Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen
SG171690A1 (en) Treatment of protein degradation disorders
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
CR20200465A (es) Agentes anticuerpos anti-cd25
ATE526987T1 (de) Dr5-antikörper und deren verwendung
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
TW200740844A (en) Novel MAdCAM antibodies
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2007011064A (es) Anticuerpos contra cd38 para tratamiento de mieloma multiple.
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
MX2009010034A (es) Pirimidodiazepinas sustituidas utiles inhibidores de la plk1.
UA94707C2 (en) Antigen-binding molecule capable of binding to plgf
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
MA32140B1 (fr) Utilisation d'un anticorps anti-cd20 de type ii à cytotoxicité cellulaire accrue dépendant des anticorps (adcc) combiné au cyclophosphamide, à la vincristine et à la doxorubicine pour traiter les lymphomes non hodgkiniens
DE602005016773D1 (de) Antikrebs-antikörper mit reduzierter komplementfixierung
MX2020011789A (es) Anticuerpos monoclonales contra claudina-18 para el tratamiento de cancer.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
TW200716132A (en) Novel chemical compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1896507

Country of ref document: EP